OncoHost Develops Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients
OncoHost developed a novel computational model for predicting significant immune-related adverse events in NSCLC patients.
Read More
Search Results for: lung cancer
Thermo Fisher and Boehringer Ingelheim Sign CDx Agreement to Select NSCLC Patients for Targeted Therapy
Collaboration leverages two CDx assays from Thermo Fisher to support greater access to genomic testing for cancer patients.
Read More
How Clinical Diagnostics Will Drive Precision Medicine
For Strata Oncology, clinical diagnostics is critical for the move to a precision medicine model. It’s doing so with its Strata Select test.
Read More
FDA Approves Fountain Medicine’s CDx for Eli Lilly’s Retevmo to Treat Solid Tumor Patients
The genomic profiling test is approved to identify patients with solid tumors with RET gene fusions who may benefit from Retevmo treatment.
Read More
Blood Tests Identify NSCLC Patients Who May Benefit from Immunotherapies
Liquid biopsies may identify NSCLC patients undergoing immunotherapy who could benefit from treatment with additional drugs.
Read More